PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study
Conclusions: This long-term follow-up study of 18 pts with MF who received PRM-151 for a median of 31 months showed the drug to be well tolerated. An overall improvement in BM reticulin and collagen fibrosis grade, as well as reductions in MPN-SAF TSS and splenomegaly were observed. In a subset of pts for whom bone marrow fibrocyte immunostaining data were available, a mean reduction in fibrocyte counts was observed, as well as improved bone marrow reticulin and collagen fibrosis grade. These data warrant confirmation in a larger controlled study.Figure.DisclosuresVerstovsek: Incyte: Consultancy; Italfarmaco: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees. Pozdnyakova: Promedior, Inc.: Consultancy. Mesa: Promedior: Research Funding; Incyte: Research Funding; Ariad: Consultancy; Novartis: Consultancy; Celgene: Research Funding; Galena: Consultancy; Gilead: Research Funding; CTI: Research Funding. Foltz: Incyte: Research Funding; Promedior: Research Funding; Gilead: Research Funding; Novartis: Consultancy, Honoraria, Research Funding. Mascarenhas: Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Merck: Research Funding; ...
Source: Blood - Category: Hematology Authors: Verstovsek, S., Hasserjian, R. P., Pozdnyakova, O., Veletic, I., Mesa, R. A., Foltz, L., Mascarenhas, J., Ritchie, E. K., Palmer, J., Silver, R. T., Kremyanskaya, M., van den Blink, B., Gupta, R., Manshouri, T., Yin, C. C., Estrov, Z. E., Gotlib, J. R. Tags: 634. Myeloproliferative Syndromes: Clinical: Emerging Therapies and Prognostic Scoring in Myelofibrosis and Other MPNs Source Type: research
More News: Bone Marrow Aspiration and Biopsy | Employment | Hematology | Merck | Myeloproliferative Disorders | Pfizer | Pharmaceuticals | Study